GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.
A Drop in the Bucket: Blood Tests and the Evolving Landscape of Alzheimer's Diagnosis
The world of Alzheimer's research is constantly evolving, a relentless pursuit of unraveling the complexities of this devastating neurodegenerative disease. Just recently, a significant milestone was reached, one that could potentially reshape the way we approach diagnosis. The Food and Drug Administration (FDA)
The Potential of Obicetrapib: Bridging the Gap Between Cardiovascular Health and Alzheimer's Disease
The intricate relationship between cardiovascular health and cognitive function has become increasingly apparent in recent years. Emerging research suggests that what impacts the heart and vascular system may also significantly influence brain health, and vice versa. Among the burgeoning areas of investigation is the potential repurposing of cardiovascular drugs for neurological conditions, specifically Alzheimer's disease. Obicetrapib
INmune Bio: Alzheimer’s Trial Results and Stock Shock
The recent news surrounding INmune Bio has sent ripples through the biotechnology investment world, causing the company's stock to plummet by over 50%. This dramatic drop wasn't due to a scandal or financial mismanagement, but rather the outcome of a clinical trial for their Alzheimer's disease drug, XPro.
Bridging the Gap: Understanding Digital Mental Health Tools in Everyday Healthcare
Mental health is a crucial part of our overall well-being, yet for many people, especially those in underserved communities, getting the right mental health care can be incredibly difficult. They might face numerous obstacles, like a lack of local specialists, high costs, or the stigma often associated with seeking mental health support. This is where Integrated Primary Care (IPC) settings come into play.
A Simple Blood Test Revolutionizes Alzheimer's Care: Why Roche's FDA Greenlight Changes Everything
The landscape of Alzheimer’s disease diagnosis and treatment is on the cusp of a dramatic transformation, thanks to the recent US Food and Drug Administration (FDA) clearance of a novel blood-based test developed by Roche. This approval is not just another step in medical technology; it signifies a potential "care paradigm shift" by introducing a simple, accessible tool that can efficiently evaluate the risk of Alzheimer’s disease pathology, particularly in primary care settings.
Remote Relief: How Virtual Support Boosts Mood and Confidence for Families Facing Dementia
Dementia is a health crisis sweeping the globe. Experts estimate that roughly 50 million people worldwide are currently living with this condition. That enormous figure is expected to nearly double to 80 million by 2030 and potentially surpass 150 million by 2050. Alarmingly, a new dementia diagnosis happens every three seconds.
Demystifying Glassbury AI: Transforming Complex Medical Data into Clear Solutions
Discover how Glassbury AI standardizes complex multi-omic datasets and Electronic Health Records to create reliable, cross-verified clinical AI models in simple, accessible terms.
Why New Alzheimer’s Treatments are Leaving Atypical Patients Behind
There is a massive blind spot in the current landscape of neurodegenerative care, and it’s one that should keep every health-tech developer awake at night. For decades, the public and medical consciousness has viewed Alzheimer’s disease through a single, narrow lens: the loss of memory. We imagine the grandmother who forgets a name or the father who loses his keys.
Lecanemab Real-World Safety: Duke Health Study Insights for Alzheimer’s Patients
For decades, the search for a way to slow down Alzheimer’s disease felt like chasing a horizon that never got closer. However, the arrival of anti-amyloid therapies like lecanemab has shifted the conversation from "what if" to "how." While clinical trials provide a controlled environment to test these drugs
Dementia Risk After 90: New Study Shows Why We're Never In the Clear
It is a common and comforting assumption: if you or your loved ones can make it to 90 years old with a sharp mind, you have somehow beaten the odds. We tend to think that after a certain milestone, the risk of cognitive decline plateaus, and we can finally breathe a sigh of relief.
Inside the Brain's Folding Architecture: How 3D Genome Structure Holds the Key to Alzheimer's
Learn how 3D genome folding in neurons impacts Alzheimer's disease. Discover the University of Pittsburgh's breakthrough research on chromatin remodelers and brain cell architecture.
Beyond Clearing Trash: Blocking the IDOL Enzyme Could Revolutionize Alzheimer's Care
Indiana University researchers have discovered that blocking the IDOL enzyme in neurons doesn't just clear toxic Alzheimer's plaques—it also lowers genetic risk (APOE4) and builds cognitive resilience. Read on to learn how this discovery could pave the way for a revolutionary new pill.
Heart Health and Brain Shrinkage: Why Your Pulse Matters for Your Mind
We often think of the heart and the brain as two separate systems—the pump and the computer. However, a groundbreaking study from Vanderbilt University Medical Center, recently highlighted in the journal Alzheimer's & Dementia, suggests that these two organs are more closely linked than we ever imagined.